Cibc World Market Inc. Makes New $5.03 Million Investment in Medpace Holdings, Inc. $MEDP

Cibc World Market Inc. acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,788 shares of the company’s stock, valued at approximately $5,033,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Quent Capital LLC acquired a new stake in Medpace during the 3rd quarter valued at $25,000. Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Employees Retirement System of Texas bought a new stake in shares of Medpace during the second quarter worth $36,000. Root Financial Partners LLC acquired a new stake in shares of Medpace in the third quarter valued at $38,000. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of research analyst reports. TD Cowen reissued a “sell” rating on shares of Medpace in a report on Friday, October 24th. Robert W. Baird raised shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target for the company in a report on Tuesday, February 10th. Barclays reduced their price objective on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a report on Wednesday. Mizuho set a $582.00 target price on Medpace in a research report on Wednesday. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average price target of $487.36.

Medpace Stock Up 2.9%

MEDP stock opened at $428.03 on Friday. The business’s fifty day moving average is $567.52 and its 200-day moving average is $538.35. The company has a market cap of $12.15 billion, a P/E ratio of 27.98, a price-to-earnings-growth ratio of 2.05 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the previous year, the firm earned $3.67 earnings per share. The firm’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 270,533 shares of company stock worth $163,122,826 in the last three months. 20.30% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.